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Abstract 
Acute lymphoblastic leukemia (ALL) is the most frequent cancer found in 
children and results from the clonal expansion of transformed lymphoid precursors. 
Approximately 15% of pediatric ALL patients present with a T-cell phenotype (T-
ALL). Despite the recent improvements in the treatment of T-ALL, there are still a high 
number of relapses and the intensive chemotherapeutic regiments used are associated 
with long-term severe complications. In order to develop new therapeutic strategies that 
can further increase efficacy while reducing side effects, one needs to better understand 
the pathobiology of T-ALL. In particular, it is necessary to understand how 
microenvironmental and cell-autonomous mechanisms influence the initiation and the 
progression of leukemia. The present thesis has the preocupation of exploring the 
mechanisms by which both an extracellular cue (IL-4) and a cell-intrinsic transcription 
factor (TAL1) may partake in leukemia development and maintenance. 
Interleukin-4 (IL-4) is a γ-common chain cytokine produced within the bone 
marrow microenvironment that is known to promote the in vitro proliferation of T-ALL 
cells. In Chapter 2, we present evidence that IL-4 induces primary T-ALL cell cycle 
progression from G0/G1 into S and G2/M, by up-regulating cyclin D2, E and A and 
down-regulating the cyclin-dependent kinase inhibitor p27
kip1
. Transfection of T-ALL 
cells with the VP22-p27
kip1
 fusion protein, which is able to translocate into the 
cytoplasm and nucleus of target cells, abrogates IL-4-mediated proliferation. This 
indicates that p27
kip1
 downregulation is mandatory for cell cycle progression of T-ALL 
cells stimulated with IL-4. Furthermore, IL-4 stimulates mTOR activation, as 
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determined by increased phosphorylation of its downstream targets p70
S6K
, S6 and 4E-
BP1. Inhibition of mTOR signaling with rapamycin prevents IL-4-induced T-ALL cell 
growth, cell cycle progression and proliferation. Our results identify mTOR as a critical 
regulator of IL-4-mediated effects in T-ALL cells and support the rationale for using 
mTOR pharmacological inhibitors in T-ALL therapy (Cardoso et al. Leukemia 2009).       
The basic helix-loop-helix transcription factor TAL1 is aberrantly expressed in up 
to 65% of T-ALL patients. LMO2, a Lim-only domain protein, is often co-expressed 
ectopically with TAL1 in this malignancy. These genes appear to have leukemogenic 
potential, since both TAL1 and LMO2 transgenic mice develop leukemias of T-cell 
phenotype. However, it is still unclear whether TAL1 is effectively leukemogenic in 
humans, or whether merely participates as a secondary event in the transformation 
process in T-ALL. To address this question, we transduced hematopoietic progenitors 
with TAL1 and/or LMO2 and co-cultured them with OP9-Dll1 stromal cells, which have 
the capacity to induce T-cell differentiation in vitro. We found that TAL1 and LMO2 
genes deregulate human T-cell differentiation in stromal cell co-cultures. Interestingly, 







 T-cell precursors with increased cell size. This observation is 
particularly interesting given that TAL1-expressing patients normally display a similar 
phenotype. These preliminary results show that TAL1 and LMO2 can disrupt normal 
human T-cell development, therefore likely predisposing thymocytes to malignant 
transformation (Chapter 3). 
In our effort to characterize the mechanisms by which TAL1 might promote T-
cell leukemogenesis, we developed a TAL1 inducible system, by fusing TAL1 with the 
hormone binding domain (HBD) of the estrogen receptor (ER), which we expressed in a 
TAL1-negative T-cell line. Upon 4-Hydroxi-Tamoxifen (4OHT) treatment, ER-TAL1 
fusion protein is able to translocate into the nucleus and consequently trigger its 
transcriptional program. Gene expression profiling of 4OHT-treated HPB-ALL cells 
stably transduced with the ER-TAL1 fusion revealed a total of 26 genes up- or down-
regulated by TAL1 activation, in at least two independent experiments. We selected 
seven of those genes on the basis of their function/potential interest in cancer and 
confirmed the differential expression of three (CASZ1, DMGDH and OR5M3) by qRT-
PCR. Accordingly, transfection of another TAL1-negative T-ALL cell line, P12, with 
TAL1, also led to increased expression of the validated TAL1 target genes. The possible 
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involvement of CASZ1 in TAL1-mediated anti-apoptotic and proliferative effects in T-
ALL cells was subsequently investigated. Knock-down of TAL1 with siRNA in the 
TAL1-positive T-ALL cell line Jurkat decreased the expression of CASZ1, correlating 
with loss of cell viability. Moreover, CASZ1 knockdown in Jurkat cells led to 
functional effects similar to those of TAL1 knockdown, namely a decrease in survival 
and proliferation. Overall, these studies allowed the identification of three novel TAL1 
downstream targets, likely with functional relevance for TAL1-mediated leukemogenic 
potential (Chapter 4). 
TAL1 binds to repressive chromatin complexes, namely involving HDAC1, and 
incubation with HDAC inhibitors (HDACis) promotes apoptosis of leukemia cells 
derived from TAL1 transgenic mice. In Chapter 5, we evaluated the impact of HDACis 
on TAL1 from a somewhat different perspective, namely by analyzing their impact on 
TAL1 expression rather than transcriptional activity. We found that incubation of T-
ALL cells with HDACis strikingly down-regulates TAL1 protein expression. This is 
due to decreased TAL1 gene transcription in cells with an intact TAL1 locus, and to 
impaired TAL1 mRNA translation in cells that harbor the TAL1
d
 deletion. Importantly, 
HDACi-induced apoptosis of T-ALL cells is significantly reversed by TAL1 forced 
over-expression. Our results indicate that the HDACi-mediated apoptotic program in T-
ALL cells is partially dependent on the down-regulation of TAL1 expression, and 
suggest that integration of HDACis into T-ALL treatment protocol may be of potential 
therapeutic benefit (Cardoso et al, Leukemia 2011, advance online publication). 
Taken together, the results described in this thesis highlight the importance that 
microenviromental factors, such as IL-4, might have in the progression of T-ALL (for 
instance, by activating mTOR and promoting cell cycle progression), and hint on the 
importance that cell-autonomous factors, such as TAL1 and LMO2, may have in 
predisposing T-cells for malignant transformation and promoting survival of T-ALL 
cells.  Importantly, our results further demonstrate that both extracellular cues and 
intracellular molecular lesions can constitute targets for therapeutic intervention in T-
ALL. 
 
